ILTOO Pharma

Interleukin-2 traditionally has been associated with nasty toxicities like the potentially fatal, flu-like cytokine release syndrome, but these days – with Nektar Therapeutics ' NKTR-214 up on a pe

Approval in 2011 of Bristol-Myers Squibb Co. 's CTLA-4 checkpoint inhibitor Yervoy (ipilimumab) in melanoma signaled the start of the immunotherapy revolution in the field of cancer therapy, foll

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal in